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ABSTRACT
Objective: Colorectal cancer (CRC) screening uptake
remains poor. Until we understand patient motivation and
preferences for undertaking screening, it is unlikely the
uptake will be optimal. Our objective is to examine patient
preferences for CRC screening modalities and uptake rates
using utility-based methods.
Methods: The preference survey was mailed to a random
sample of Canadian subjects aged 40 to 60 years from a
primary care network. A fractional factorial experimental
design maximized D-efﬁciency and included four blocks
with 12 choice tasks in a conditional two-step design,
two-alternative discrete choice format with ﬁve screening
attributes (process, pain, preparation, sensitivity, and speci-
ﬁcity). Bivariate probit regression analysis was used to esti-
mate patient preferences for attributes, choice probabilities
for alternative modalities and expected rates of uptake.
Results: Five hundred forty-seven of 1047 surveys were
returned. Almost 30% of respondents preferred no screening.
The most preferred test attribute levels were noninvasive
process (e.g., CT), no preparation, no pain, 100% speciﬁcity,
and 90% sensitivity. Accuracy-related attributes were
more important than test process-related attributes. Virtual
colonoscopy was the most preferred, followed by colonos-
copy, barium enema, sigmoidoscopy, and fecal DNA testing,
based on simulated choice probability estimates. Fecal occult
blood testing (FOBT) was least preferred. Adjusted screening
uptake rate estimates showed the greatest impact (42%
increase) would be achieved if all CRC screening modalities
were available rather than FOBT alone.
Conclusions: Our ﬁndings emphasize the important role of
patient preferences for no screening and in selecting alterna-
tive CRC screening modalities. CRC screening implementa-
tion in Canada should consider patient preferences to
optimize uptake.
Keywords: colorectal cancer screening, conjoint analysis,
discrete choice experiment, patient preferences, stated
preferences.
Background
Colorectal cancer (CRC) accounts for approximately
13% of all cancers diagnosed in Canada. Because
of its high incidence, long precancerous phase, and
more favorable prognosis at earlier stages, CRC is
considered a promising target for population-based
screening [1]. Several screening modalities can be
adopted, including fecal occult blood testing (FOBT),
ﬂexible sigmoidoscopy (SIG), colonoscopy (COL),
and double-contrast barium enema (DCBE). Recent
economic analyses suggest that all of these strateg-
ies meet conventional criteria for cost-effectiveness
[2–4].
In the United States, CRC screening is recommended
using any of the available methods. In contrast, no
Canadian province has a formal CRC screening
program in place [5]. Several Canadian provinces and
organizations are actively considering screening pro-
grams [6–9]. Thus, it is important to understand pref-
erences for screening in the Canadian population where
relatively few people have had CRC screening.
A key factor driving the success or failure of any
screening program is patients’ willingness to undergo
the screening test. Even in the United States, where all
available CRC screening modalities are promoted and
screening is reimbursed, uptake is poor. Approxi-
mately 50% of individuals older than 50 years of age
have ever been screened using any screening method
[10]. It has been shown that interventions aimed at
increasing knowledge do not necessarily help to
increase the uptake or adherence to an intervention
[11]. As such, until we understand the motivation for
undertaking or choosing not to undergo CRC screen-
ing and patient preferences for alternative CRC
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screening modalities, it is unlikely that CRC screening
programs will be successful in optimizing uptake.
The important role of patient preferences in CRC
screening, and in medical decision-making in general,
has garnered increased attention [12,13]. At the same
time, although there is broad recognition that provid-
ers and patients must appreciate and weigh multiple
dimensions in choosing a CRC screening test, there has
been little empirical work to measure or guide this
process. For example, previous surveys have identiﬁed
that there is substantial variation in patient preferences
for CRC screening, and have examined the order of
importance of various features of the modalities [14]
and preferences for CRC screening programs [15], but
not the magnitude of preferences for the alternative
CRC screening modalities.
There are no data available about CRC screening
modality preferences in Canada. As such, the objective
of the current study was to measure and quantify
Canadian preferences for various CRC screening tests
and for a “no-screening” option using utility-based
methods. In addition to identifying and quantifying the
importance of the key attributes of CRC screening
tests, these results may provide some insight to guide
policy decisions on the implementation of CRC screen-
ing programs with respect to initial uptake. The design
of this study represents a methodological advance over
existing studies by using utility-based methods that
include a “no screening” option so that screening
uptake can be estimated from the results. This infor-
mation is also timely given the current discussions
about piloting and implementing CRC screening in
Canada, and they are also relevant to other popula-
tions by providing more detailed information about
preferences.
Methods
Choice-Format Stated Preference Surveys
Conventional strategies for CRC screening vary con-
siderably in features of both process (e.g., invasiveness
and convenience) and outcome (e.g., diagnostic error)
features [13,16–21]. Process attributes are not cap-
tured by more conventional preference-based outcome
measures such as the quality-adjusted life-year, which
has been used previously to evaluate CRC screening
[22]. Choice-format stated preference survey methods,
sometimes referred to as conjoint analysis or discrete
choice experiments, is a powerful technique for mea-
suring consumer preferences for goods and services
[23]. With strong roots in economic theory and design
of experiments, this methodology has been adapted to
evaluate health services [23–25]. It is well suited for
CRC screening preferences because it is designed to
measure quantitative trade-offs among multi-attribute
choices, including aspects of both process and
outcome. Choice-format stated preference survey
results can be used to model preferences for individual
attributes, determine relationships among attributes,
and estimate the relative utility of combinations of
attributes that represent real or hypothetical CRC
screening programs. We use utility in the conventional
sense of a general index of individual satisfaction. It is
ordinal in the sense that the index is not scaled
between zero and one and is unique under any positive
afﬁne transformation.
Undertaking a choice-format stated preference
survey entails several steps: 1) identifying key at-
tributes; 2) assigning levels to the attributes; 3) selecting
the format of the survey; 4) developing scenarios that
describe services deﬁned by various combinations of
attributes and levels; 5) eliciting preferences; and 6)
analyzing choice data to quantify the beneﬁt of offering
more favorable testing options [25–29]. These steps
provide a framework for our approach [27,28,30].
Deﬁnition of attributes. A preliminary menu of
attributes was prepared through literature review and
expert consultation. Focus groups were conducted
using a semistructured interview guide. An extensive
list of CRC screening attributes was generated by ini-
tially presenting each participant with a restricted list.
This was used to stimulate the discussion about fea-
tures of the test, and the moderator probed to elicit
additional attributes. In a modiﬁed Q-sort exercise
[31], each participant reviewed a list of 16 attributes
(false negative rate, false positive rate, change in risk of
cancer, risk of complications, “one-stop shopping,”
invasiveness of procedure, change in risk of cancer
death, fear/stress from results, preparation required for
testing, length of time for testing, length of time for
recovery, pain, embarrassment, need for follow-up
testing, how frequently the test must be repeated, cost
of the test), assigned one or more points to them (using
10 self-adhesive dots, each worth one point) and
discussed their choices with the group. Audiotaped
sessions were transcribed verbatim by a professional
transcriber and analyzed by an experienced qualitative
researcher using the editing style of analysis to label
text segments by theme, focus group and respondent.
Major and minor themes were identiﬁed, linked to raw
data and ﬁndings were summarized in text and tabular
form before interpreting in light of current literature
and discussions with research team members [32,33].
A series of eight of these structured focus groups
helped deﬁne ﬁve attributes (process, pain, prepara-
tion, speciﬁcity, sensitivity) (Appendix A) as the most
important to respondents and most relevant to policy
decisions involving CRC screening modalities. It was
evident from the focus groups that each of these
attributes was a distinguishable feature of CRC screen-
ing modality. Focus group participants were also able
to differentiate between speciﬁcity and sensitivity of
the screening test.
416 Marshall et al.
Because the purpose of this study was to focus on
uptake of CRC screening modalities, we deliberately
did not consider attributes of screening programs, such
as the interval to next screening and the impact on
cancer mortality. In addition, we also included a cost
attribute to facilitate estimating the sensitivity of
uptake to possible variations in copay levels. The
details of this process and the ﬁndings are reported
elsewhere [34, Lohfeld et al., submitted]. The same
focus groups were used to pilot test the survey to
ensure that attributes were comprehensive, unique,
and clearly deﬁned.
Assignment of attribute levels. For each selected
attribute, several potential values or levels were
deﬁned (Appendix A). These were chosen to represent
both currently plausible values and those that might be
achieved with novel screening modalities. For
example, the sensitivity of COL, and DCBE for detec-
tion of CRC is at least 90% [35,36], whereas that of
FOBT and fecal DNA assays is estimated by some
sources to be 60% or less [35,37]. Accordingly, values
from 40% to 90% were assessed in the survey.
Survey format. The survey used a conditional two-
step design, in a two-alternative discrete choice format
with binary responses [38]. For each choice task, sub-
jects were ﬁrst asked to identify which of two hypo-
thetical screening modalities they would prefer (Choice
1: A vs. B) [39]. Subjects were then asked to choose
between that preferred screening modality (A or B) and
no screening (Choice 2). This design maximizes the
information obtained on both the marginal rates of
substitution among modality attributes and condi-
tional uptake rates. An example of a choice task from
the survey is provided in Appendix B.
Scenario design. The survey attributes and levelswould
allow 216 unique attribute combinations, excluding
cost, in a full factorial design (4 ¥ 2 ¥ 3 ¥
3 ¥ 3). Thus, as is common practice, a fractional facto-
rial designwas used to identify a subset of combinations
that could estimate preference weights for all attributes
while minimizing the number of paired comparisons
[40,41]. This design was developed using the SAS
Optex procedure and optimized several measures of
efﬁciency in a general linear model [41]: 1) level balance
(i.e., levels of an attribute occur with equal frequency);
2) orthogonality (i.e., the occurrence of any two levels
of different attributes is uncorrelated); and 3)
D-efﬁciency (the partworth estimates for a D-efﬁcient
design have the smallest possible standard errors, given
the sample size, and number of partworths). Each sce-
nario included two to three overlaps (attributes whose
levels are the same for both alternatives).
The design allowed estimation of two attribute
interactions: preparation and pain, and speciﬁcity and
sensitivity based on our initial hypotheses. Neither of
these interaction terms is statistically signiﬁcant and is
not reported here. We also included interaction terms
between no screening and demographic characteristics
that were chosen based on theory and prior ﬁndings.
In pilot testing, we found that respondents could
easily complete up to 15 choice tasks. The ﬁnal frac-
tional factorial design included 40 choice tasks divided
among four blocks. Each respondent completed one
of four surveys containing 10 choice tasks plus
two common “warm up” choice tasks. Each block
of choice tasks was presented in two alternative
sequences to minimize order effects.
Survey administration to elicit preferences. Subjects
were recruited from the Stoney Creek and Mountain
Primary Care Network (PCN) in Hamilton Ontario.
This PCN provides primary health-care services to
patients in the region through a collaborative network
of family practitioners. A random sample of 1170
patients was selected from a roster of 9959 patients
aged 40 to 60 years. The family practitioners reviewed
the lists to exclude those who: 1) had a history of CRC;
2) were institutionalized; 3) did not understand sufﬁ-
cient English; or 4) who were otherwise incapable of
completing the questionnaire. The remaining patients
(n = 1047) were assigned to receive one of eight ver-
sions of the survey (four blocks of choice tasks with
two sequences).
Survey packages were marked with unique identiﬁ-
cation numbers and distributed by mail. Each package
included: 1) a letter of introduction from the family
physician; 2) the survey with instructions; 3) an infor-
mation sheet to deﬁne medical terminology; 4) a
self-addressed envelope; and 5) a $1 gift certiﬁcate.
Respondents who returned surveys by a speciﬁed dead-
line were entered in a prize draw for dinner at a local
restaurant. Following Dillman’s [42] approach to
enhance response rates, reminder cards were sent to
nonresponders after 2 weeks, and complete survey
packages were sent again after 30 days.
Following standard procedures for conjoint analy-
sis survey administration, survey respondents were
provided with 1) a description of CRC screening, the
options and the risk of CRC in the general popula-
tion (Appendix C); 2) a description of the decision-
making situation; and 3) an example of how to
complete a survey question. The patient is asked to
consider a situation where their own doctor has rec-
ommended them to consider screening for colon
cancer. Based on the two tests described in each ques-
tion, patients are asked to select and mark the screen-
ing test that they would prefer, assuming that these
are the only two options that are available to them.
Furthermore, the cost attribute is explained in the
context of what the patient would have to pay to
have the test done.
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In addition to the choice tasks, the survey inquired
about demographic data such as age, sex, level of
education, employment status, and household income,
uptake of other cancer screening tests, and lifestyle
behaviors. The survey was designed for completion
within 15 min.
Respondents were almost evenly split in terms of
sex (51% male) with a mean age of 50.9 years
(SD = 5.96) (Table 1). The respondents in this sample
were highly educated, with 93% having completed
high school or a higher-level degree, 82% having an
income of $30,000 or more, and most being employed
full time (60%). Almost all respondents reported good
or better health and only 12% reported a family
history of CRC. Most had heard of FOBT (64%) and
SIG (84%), but only a minority had heard of DCBE
(30%) or COL (28%). Sixty-seven percent of female
respondents indicated that they had undergone mam-
mography testing to screen for breast cancer. The study
population was similar in sex [43], employment status
[44], and education [45] to the Canadian population
based on estimates for a similar age range reported in
the 2001 Statistics Canada census The annual house-
hold income more than $50,000 [46], however, was
higher in the study population than the national esti-
mates (65% vs. 42%).
Data analysis. Of 1047 surveys mailed, a total of 547
were returned (response rate = 52%). Results are
reported for all 547 respondents, except where obser-
vations were dropped by default in the regression
analyses because of missing responses.
Demographics
Respondents’ demographics, health status, family
history of CRC, and awareness of CRC modalities
were summarized descriptively using means (SD) and
ranges (minimum and maximum) for continuous vari-
ables, and number of responses (percent) for categori-
cal variables (Table 1).
Model Estimation
Stochastic utility maximization theory provides a well-
established conceptual framework for modeling indi-
vidual preferences [41,47]. Random utility models
were used to deﬁne the utility of choice alternatives
deﬁned as a function of the attributes. Respondent’s
utility or satisfaction from testing is speciﬁed as linear
in test features and the utility of not testing is an
alternative-speciﬁc constant:
Vtest stool scope CT noprep diet nopain
spec=100%
= + + + + + +
+
β β β β β β
β βspec=80% sens=90% sens=70%
cost test
+ + +
+
β β
β ε (1)
Vnotest o age male college income
healthstatus crc
= + + + + +
+
(β β β β β
β β history notest notest) × +D ε (2)
The Vtest b parameters can be interpreted as relative
importance weights. Because individual-speciﬁc char-
acteristics are constant for any pair of test alternatives,
they vanish from the utility differences that determine
choices among competing tests unless they are inter-
acted with one or more test features. In this speciﬁca-
tion, we interacted several demographic and health
variables (deﬁned below) with Dnotest, a dummy vari-
able indicating that the respondent picked the no-
test option. These parameters indicate the effect of
Table 1 Self-reported characteristics and history of respon-
dents (n = 547)
Characteristic n (%)
Age (years)
Mean 50.9
SD (minimum–maximum) 6.0 (40–61)
Sex
Male 280 (51)
Missing 1 (<1)
Highest level of education
Public or primary 37 (7)
High school 259 (47)
College or university 213 (39)
Graduate degree 34 (6)
Missing 4 (<1)
Annual household income in Canadian dollars ($)
<10,000 12 (2)
10,000–29,999 62 (11)
30,000–49,999 106 (19)
50,000–69,999 123 (23)
70,000–89,999 87 (16)
90,000 or more 131 (24)
Missing 26 (5)
Current employment status
Employed full-time 327 (60)
Employed part-time 47 (9)
Self-employed 55 (10)
Homemaker 39 (7)
Unemployed 18 (3)
Retired 57 (10)
Missing 4 (<1)
Cultural background
North American (Canadian or American) 394 (72)
European 88 (16)
British 40 (7)
Asian 15 (3)
Caribbean 3 (1)
Other 5 (1)
Missing 2 (<1)
Health status
Excellent 77 (14)
Very good 233 (43)
Good 181 (33)
Fair 44 (8)
Poor 11 (2)
Missing 1 (<1)
Family history of CRC
Yes 66 (12)
Do not know 36 (7)
Missing 3 (<1)
Awareness of CRC screening modalities
Fecal occult blood test 352 (64)
Double-contrast barium enema 164 (30)
Sigmoidoscopy 461 (84)
Colonoscopy 154 (28)
CRC, colorectal cancer.
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individual characteristics on testing uptake. The error
terms etest and enotest arise because utility is stochastic
from the observer’s point of view [48]. We estimated
the parameters using bivariate probit because the
choice between two hypothetical tests followed by a
test/no test choice question are correlated. We assume
the variance of etest is 1, the variance of enotest is l, and
their covariance is 1/(2 ¥ l).
The reference levels for each attribute were those
found to be least preferred (barium enema for the
process attribute, laxatives for the preparation
attribute, mild pain for the pain attribute, 50% for the
speciﬁcity attribute, 40% for the sensitivity attribute).
Categorical test characteristics were effects coded,
whereas cost was treated as a continuous variable.
Standard maximum-likelihood techniques were used
to estimate the parameters for this model.
We transformed the bivariate probit parameter esti-
mates to standard logit form to facilitate calculations
of uptake simulations [49]. The standard logit speciﬁ-
cation allows calculating the predicted choice prob-
abilities for any assumed subset of tests. We can then
use the estimated utility scores to calculate predicted
uptake probabilities for any hypothesized set of com-
peting tests. For example, the probability of choosing
Test i when the alternatives include Test i, Test j, Test
k, and No Test is [50]:
Pr ,
exp
.
exp
ob(Test i )Test i Test j, Test k, No Test
Test i
=
⎛⎝⎜ ⎞⎠⎟
V
λ 1 6
V V
V
Test i Test j
Test k
λ λ
λ
1 6 1 6
1 6
.
exp
.
exp
.
⎛⎝⎜ ⎞⎠⎟ + ⎛⎝⎜ ⎞⎠⎟ +
⎛⎝⎜ ⎞⎠⎟ + exp .
VNo Test
λ 1 6
⎛⎝⎜ ⎞⎠⎟
⎡
⎣
⎢⎢⎢⎢
⎤
⎦
⎥⎥⎥⎥
(3)
Equation 3 makes it possible to simulate how pre-
dicted uptake varies depending on which tests are
available and what features the available tests have.
For example, if the exponentiated utilities for alterna-
tives i, j, k, and no test are 1, 1.5, 2.5, and 4, respec-
tively, then the predicted uptake rate for Test i is about
0.15 if only alternatives i, j, and no test are available.
However, if the more attractive test k is made avail-
able, its predicted uptake will be about 0.25 and the
uptake for Test i will fall to about 0.10.
Demographic Comparisons
The following personal characteristics were included
in the ﬁnal regression model as categorical variables:
age (>median age vs. median age, median
age = 51 years), sex (male vs. female), education
(college vs. <college), annual household income
(median income vs. <median income, median
income = $60,000 CDN), self-reported health status
(excellent or very good vs. good, fair or poor), and
family history of CRC (relative with CRC vs. no rela-
tive with CRC).
Consistency Tests
It is important to test for consistency of responses to
assess the reliability of the responses. We assessed con-
sistency in two ways. First, individual responses were
assessed for violation of the tenet of monotonic pref-
erences, wherein individuals prefer more of any
normal good [24,51]. For this purpose, the two
warm-up scenarios in each choice-format stated pref-
erence survey were designed as “dominant-pair” tests
where all attributes favored one alternative. Other
dominant pair tests arose randomly as per the experi-
mental design. Second, we identiﬁed respondents with
preferences whose responses seem to indicate unwill-
ingness to trade a given attribute against other
attributes. A respondent was considered unwilling to
trade if they made the same choices in at least 8 of 10
scenarios with that attribute. If a respondent failed
either of these consistency tests, he was considered
inconsistent. We ran the models both including all
respondents and deleting inconsistent respondents.
Coefﬁcient signs were unaffected, and differences in
the coefﬁcients were insigniﬁcant using Wald tests
(P < 0.05). Thus, we decided to retain all respondents
in the ﬁnal analysis.
Models were evaluated for goodness of ﬁt using the
likelihood ratio chi-square statistic for the global test
of zero model coefﬁcients and McFadden’s pseudo
R-squared. Overall, the ﬁnal model ﬁt was good (like-
lihood ratio chi-square statistic (P < 0.0001) and
McFadden’s pseudo R-squared = 0.1940). The model-
ing results are expressed as estimates, corresponding
95% conﬁdence intervals, and P-values. All statistical
analyses were performed using GAUSS version 6.0
(Aptech Systems, Inc Black Diamond, WA, USA).
The ﬁnal model results were used to:
1. Evaluate the relative importance of the attributes
and attribute levels. It was expected that the most
important attributes would be sensitivity and
speciﬁcity, followed by pain, preparation, and
cost. It was predicted a priori that respondents
would prefer CRC screening modalities that had
high sensitivity and speciﬁcity, were noninvasive
with no pain or preparation, and had a small cost.
2. Estimate the predicted choice probability of
various CRC screening modalities in a scenario
analysis. The predicted choice probability of com-
monly available CRC screening modalities (FOBT,
DCBE, SIG, and COL) and two modalities that
may soon be commonly available (DNA stool tests
and virtual COL) was estimated using the model
coefﬁcients for attribute levels that most closely
approximated those testing modalities. Although
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there is a range of estimates for the accuracy
[52–56], we mapped the values to the closest
attribute level available in our survey to illustrate
the effect on choice probabilities for the different
screening modalities. The values we chose were
based on cancer detection rather than polyp detec-
tion. Following standard methods for conjoint
analysis, the available attribute levels in the survey
are not always complete and accurate clinical
descriptions of the actual CRC screening tests
because of the practical limitations of the survey
format. The attribute levels in the survey therefore
focus on the most important features that distin-
guish the alternative CRC screening tests, and do
not provide an exhaustive and complete descrip-
tion of all aspects of the tests. It was expected a
priori that patients would prefer virtual COL fol-
lowed by DCBE, SIG, and FOBT.
3. Estimate the percentage increase in screening
uptake if alternative screening modalities were
made available. We used the model to estimate
expected rates of uptake for CRC screening tests
that offered different mixes of alternative
attributes.
4. Estimate the elasticity of uptake [57]. We esti-
mated the elasticity of the uptake of alternative
CRC screening modalities for a 1% increase in the
cost of the CRC screening modality as an indica-
tion of how sensitive respondents were to changes
in the price or copay.
For ease of presentation and interpretation, com-
bined direct and interaction coefﬁcient estimates were
rescaled from 0, the least desirable attribute level, to
10, the most desirable attribute level, and presented in
a ﬁgure to illustrate which attributes and levels were
most important.
Results
Overall, the proportion of responses for “no CRC
screening” in the second choice question in each choice
task on the preference survey was 28.9%. This means
that almost 30% of the time, respondents would
choose not to have screening at all compared with the
screening test described in the ﬁrst part of the question.
Respondents preferred screening processes that were
noninvasive, required no preparation and involved no
pain, and were highly accurate. The analysis results are
further described below.
Bivariate Probit Regression Model Results (Table 2)
The parameter estimates in the main effects and inter-
action models were similar, except that the levels of
signiﬁcance changed for “scope” and “special diet.”
The model including interaction terms between no
screening and personal characteristics provided a
slightly better ﬁt than the main effects model based on
goodness-of-ﬁt tests (Table 2). Thus, the results for the
interaction model are discussed below and all subse-
quent analyses were based on this model.
Respondents preferred testing with a noninvasive
process such as CT scan, no preparation, no pain,
100% speciﬁcity, and 90% sensitivity. In contrast,
respondents preferred not to undergo testing involving
barium enema, laxatives, mild pain, and with poor
accuracy (50% speciﬁcity and 40% sensitivity). The
attribute levels are generally well ordered and most are
statistically signiﬁcant (many at the alpha <0.001 level
of signiﬁcance). The difference in the parameter esti-
mates between attribute levels is relatively small for
some of the attributes (e.g., difference of 0.084 for
preparation attribute [diet = -0.066 and laxa-
tive = -0.150] and difference of 0.017 for process
attribute [stool = -0.043 and scope = -0.060]).
The parameter estimates for the personal character-
istics interacted with no screening were statistically
signiﬁcant at the alpha = 0.05 level of signiﬁcance.
Respondents that were older than the median age of
51 years, female, had less than a college level of edu-
cation, had an income greater than the median income
of $60,000, were in poorer health, and had a family
history of CRC were more likely to choose some type
of CRC screening compared with no screening at all.
The difference between these patient groups was great-
est and statistically signiﬁcant only for the parameter
indicating whether or not the respondent had a family
history of CRC. For all other parameters, the conﬁ-
dence intervals of the point estimates overlap.
CRC Screening Modality Attributes and Levels (Fig. 1)
The relative importance of the attributes and attribute
levels can be observed in Figure 1 where the estimates
are plotted on a scale from 0 (least desirable attribute
level of 40% sensitivity) to 10 (most desirable attribute
level of 90% sensitivity). For each attribute level,
the point estimate and 95% conﬁdence intervals is
reported.
The most important attribute, deﬁned as the largest
absolute difference between coefﬁcients for the highest
and lowest levels, was sensitivity, followed by speciﬁc-
ity, preparation, process, and pain. Accordingly,
attributes related to accuracy (sensitivity and speciﬁc-
ity) appear to be more important than attributes
related to the modality process (preparation, process
and pain). For example, the difference between no pain
and mild pain is one-seventh of the difference between
90% sensitivity and 40% sensitivity.
The most preferred attribute mix is a noninvasive
CT scan with no preparation, no pain, 100% speciﬁc-
ity, and 90% sensitivity. The least preferred attribute
mix was a barium contrast study enema with laxative
preparation, mild pain, 50% speciﬁcity, and 40%
sensitivity.
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Predicted Choice Probability for Alternative CRC
Screening Modalities (Fig. 2)
Using the interaction model results, the choice prob-
ability of current and emerging CRC screening modali-
ties were estimated in scenario analyses and are shown
in Figure 2. Each CRC screening modality was repre-
sented by the attribute levels that most closely approxi-
mated the actual values of that test. Based on this,
virtual COL is the most preferred CRC screening test,
followed by COL, DCBE, SIG, fecal DNA testing, and
ﬁnally, FOBT. This ﬁts with a priori expectations. The
ordering of preference for the alternative CRC screen-
ing modalities is driven primarily by the estimates of
accuracy (sensitivity and speciﬁcity).
Estimates of CRC Screening Uptake (Table 3)
The model results were used to examine policy rel-
evant scenarios and predict the expected rates of
uptake for CRC screening programs that offered dif-
ferent mixes of alternative CRC screening modalities.
Assuming that CRC screening uptake would be 30% if
FOBT was the only screening test available, adding
one of the other screening tests would increase uptake
24% to 30% (Table 3). The greatest impact on screen-
ing uptake, a 42% relative increase, would be achieved
if all common approaches for CRC screening were
made available (FOBT, DCBE, SIG, and COL). None-
theless, for no combination of modalities is the pre-
dicted absolute uptake rate greater than 42%. If all
common approaches for CRC screening were avail-
able, and virtual COL or fecal DNA were introduced,
the increment in CRC screening uptake would be
minimal, approximately 2%.
Estimates of Elasticity (Table 4)
The parameter for modality cost was negative, and
statistically signiﬁcant (alpha < 0.001). This indicates
that respondents paid attention to cost in evaluating
modality options.
Although the parameter estimate is statistically
signiﬁcant, its effect on uptake is very small. For all
the scenarios examined, the uptake of CRC screening
is almost perfectly inelastic (Table 4). The largest
decrease in the quantity of CRC screening demanded
Table 2 Model results—main effects and interactions
Attribute Level
Main effects model
Main effects model
and interactions
Parameter estimate
All observations
n = 541; 10,440
observations P-value
Parameter estimate
All observations
n = 541; 9920
observations P-value
Process CT scan 0.226 ‡ 0.229 ‡
Stool -0.030 § -0.043 §
Scope -0.071 † -0.060 *
Barium enema|| -0.125 § -0.126 §
Preparation None 0.223 ‡ 0.216 ‡
Special diet -0.069 ‡ -0.066 †
Laxatives|| -0.154 ‡ -0.150 ‡
Pain None 0.100 ‡ 0.095 ‡
Mild pain|| -0.100 ‡ -0.095 ‡
Speciﬁcity 100% 0.296 ‡ 0.290 ‡
80% -0.018 § -0.011 §
50%|| -0.278 ‡ -0.279 ‡
Sensitivity 90% 0.729 ‡ 0.730 ‡
70% 0.028 § 0.035 §
40%|| -0.757 ‡ -0.765 ‡
No CRC screening -2.240 ‡ -1.977 ‡
Ln (LAM) 4.487 ‡ 4.261 ‡
CRC modality cost -0.002 ‡ -0.002 ‡
Interaction terms—personal characteristics with no screening
Age greater than median -0.6842 †
Male 0.6909 †
College degree or higher 0.5425 †
Income greater than median -1.0091 †
Self-reported health very good or better 0.5322 *
Self-reported health good 0.2853 §
Has relative with CRC -2.484 ‡
Model goodness of ﬁt statistics
-2 log likelihood ratio full 11007 § 10298 §
-2 log likelihood ratio restricted 13459 § 12776 §
Likelihood ratio c2 2452 ‡ 2478 ‡
Degrees of freedom 12 § 19 §
McFadden’s Pseudo-R2 0.1822 § 0.1940 §
*P 0.05, †P < 0.01, ‡P < 0.001, §P > 0.05.
||Reference level.
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occurs with an increase in the cost of virtual COL in
the scenario where virtual COL and FOBT are the
available modalities—a 10% increase in the price
would decrease screening uptake by only 0.37%.
Discussion
To our knowledge, this is the ﬁrst study to use a
theoretically based and statistically rigorous approach
to measure preferences for CRC screening methods in
Canada. The question remains as to the most appro-
priate CRC screening method from among the existing
alternatives [58]. The results of this study identify sub-
stantial differences in the importance of various CRC
screening test attributes. We found that the respon-
dents value attributes related to accuracy (sensitivity
and speciﬁcity) more than those related to the testing
process (preparation, process, and pain). The literature
on relative preferences for CRC screening alternatives
is limited. Most studies have used qualitative survey
methods to determine the proportion of patients who
prefer alternative CRC tests, often limited to two
choices, and to identify the most important test feature
in selecting a screening method [14,59]. Our ﬁndings
are consistent with the general ﬁndings from previous
studies that examined patient choices among CRC
modalities qualitatively [14,60–63]. Other nonutility
based studies on patient preferences for alternative
CRC screening modalities have observed heterogeneity
in individual patient preferences by patient character-
istics and reported that preferences vary depending on
how patients value different test features. Nonetheless,
the ﬁndings have been reasonably consistent about
preferences for CRC screening tests with high accuracy
[59,64–66]. These studies are limited however, because
they do not reﬂect patients underlying utility values. To
measure utilities, the survey must be designed in a
format that requires respondents to trade-off among
alternative choices. This can be achieved using a
choice-based stated preference survey, as we did in this
study, which permits a quantitative understanding of
the relationship among the features of CRC screening
tests.
Among CRC screening modalities currently
endorsed by agencies such as the Canadian Task Force
on Preventive Care [67], the American Cancer Society
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from 0 to 10 and grouped by attribute to illustrate: 1) Relative importance of attributes (numbered from 1 to 5).The more critical the attribute in modality
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[68] and the US Preventive Services Task Force for
CRC screening [69], respondent preference for accu-
racy was the main reason why COL was most pre-
ferred and FOBT was least preferred. These scenario
analyses provide an estimate of preferences based on
assumptions about the attribute levels for each screen-
ing modality. Recognizing that the estimates for the
performance of each of these tests vary considerably
depending on the technology and generally do not
represent performance in the context of a population
screening program, we examined alternative estimates
in sensitivity analyses. For example, FOBT speciﬁcity
for the current rehydrated assays has been reported as
high as 97% [56]. Even in this scenario, the overall
results and conclusions about the choice probabilities
for alternative CRC screening modalities are robust.
Among emerging CRC screening modalities, we
found that virtual COL, as represented by the attribute
levels in this survey, was preferred to fecal DNA assays
[52,70] and we found that virtual COL would be the
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Figure 2 Predicted choice probabilities for alternative colorectal cancer screening modalities. COL, colonoscopy; DCBE, double-contrast barium enema;
DNA, fecal DNA; FOBT, fecal occult blood test; SIG, secigmoidoscopy;VCOL, virtual colonoscopy.
Table 3 Estimates of CRC screening uptake
Menu 1 Menu 2
% Increase in screening
uptake: menu 2 vs. menu 1Modalities available
Baseline rate of
screening uptake
Additional modalities
available
New rate of screening
uptake
FOBT 0.300 VCOL 0.391 30
FOBT 0.300 SIG 0.375 25
FOBT 0.300 COL 0.386 29
FOBT 0.300 DCBE 0.385 28
FOBT 0.300 Fecal DNA 0.371 24
FOBT, DCBE, SIG, COL 0.300 VCOL 0.307 2
FOBT, DCBE, SIG, COL 0.300 Fecal DNA 0.305 2
FOBT 0.300 DCBE, SIG, COL 0.425 42
COL, colonoscopy; DCBE, double-contrast barium enema; FOBT, fecal occult blood test; SIG, secigmoidoscopy;VCOL, virtual colonoscopy.
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most preferred of all CRC screening modalities. It is
notable that although other CRC screening modalities
are reimbursed, virtual COL is not reimbursed for
screening in the United States.
Our study also adds to the literature by using an
“opt-out” follow-up question format, a methodologi-
cal advance that allowed us to estimate the probability
of choosing no screening and infer rates of screening
uptake from the results. This format forced respon-
dents to ﬁrst choose among two CRC screening modal-
ity scenarios presented, and then choose between the
selected screening modality and the option of no CRC
screening. To our knowledge, this approach has been
not been used in other preference studies of screening.
In the context of considering CRC screening in
Canada, it is important to recognize that some propor-
tion of people will not get screened regardless of the
testing alternatives. Despite the prospect of reduced
CRC mortality, a signiﬁcant challenge to the uptake of
CRC screening is overcoming public lack of accep-
tance of the screening procedures [71]. Low screening
uptake is multifactorial, based not only on patient
preferences, but also physician preferences. A positive
attitude toward screening and physician recommenda-
tion result in high adherence whereas fear of ﬁnding
cancer and the belief that cancer is fatal result in low
adherence [72]. Previous research has shown that the
general practitioner is an important inﬂuence in the
decision to undergo CRC screening [65]. Because
FOBT is currently being pilot tested and recommended
for CRC screening in Canada, we examined the impact
of making other CRC screening modalities available in
addition to FOBT. Not surprisingly, our results suggest
that the greatest impact on screening uptake, a 50%
increase to achieve a screening uptake rate of 45%,
would be achieved if all commonly available and
endorsed CRC screening modalities were made avail-
able, and that the addition of virtual COL or fecal
DNA to an existing menu of CRC screening modalities
would only have a minimal impact on screening
uptake of approximately 2%. Although not everyone
will participate in screening, there is an opportunity to
increase screening uptake rates by offering a reason-
able range of CRC screening modality options, instead
of limiting the choice to FOBT. Based on our projec-
tions, it is not unreasonable to hypothesize that rates
could be increased to those observed in the United
States of approximately 50%. The impact of increased
CRC screening to decrease the incidence of CRC could
be signiﬁcant, based on the ﬁndings of the National
Polyp Study that CRC incidence was 76% lower in
those who had a polypectomy after a COL than the
general population [73].
The results of this study must be interpreted with
caution, particularly in the context of applying the
results to preferences for CRC screening programs. To
make the survey tractable, the attribute descriptions to
depict the CRC screening tests were simpliﬁed. For
example, the process attribute was deliberately simpli-
ﬁed to focus on the aspects of the testing process that
distinguishes each of the CRC screening test modalities
from another. Secondly, the number of attributes for
the process attribute was reduced to four instead of
ﬁve to simplify the methodological design. The conse-
quence of this is that COL and SIG, as represented in
these analyses, only differ in their sensitivity estimates.
Furthermore, this survey speciﬁcally focused on the
uptake of a single CRC cancer screening test, not an
entire screening program that involves a series of
screening tests implemented over time. This study
focuses on patient preferences for uptake of CRC
screening based on attributes of the CRC screening
tests. In addition to the simpliﬁcations of the survey
design and format to make it a practical instrument for
administration, the results may be limited in terms of
their generalizability. Given that the survey response
rate was 52%, the validity of the ﬁndings may be
affected by respondent selection bias and it is not
obvious how this would affect preference estimates for
CRC screening tests. We were not able to collect demo-
graphic information on nonresponders to determine
whether there were systematic differences between
responders and nonresponders.
This study supports the feasibility and usefulness
of choice-format stated preference methods in health
services evaluation, which is consistent with positive
ﬁndings reported by others for different diseases [27,
74–77]. Respondents found the survey feasible to com-
plete, based on the response rate and level of comple-
tion, consistency tests showed that respondents were
considering trade-offs between attributes, and the
attribute levels were ordered and demonstrated prefer-
Table 4 Modality cost elasticity estimates
New modality
FOBT + new modality
Elasticity (95% conﬁdence interval)
FOBT +DCBE + SIG + COL + new modality
Elasticity (95% conﬁdence interval)
DCBE -0.011 (-0.014 to -0.012) NA
SIG -0.012 (-0.016 to -0.009) NA
COL -0.027 (-0.035 to -0.026) NA
VCOL -0.037 (-0.048 to -0.021) -0.006 (-0.01 to -0.003)
DNA -0.018 (-0.026 to -0.016) -0.002 (-0.002 to -0.003)
COL, colonoscopy; DCBE, double-contrast barium enema; DNA, fecal DNA; FOBT, fecal occult blood test; NA, not applicable; SIG, sigmoidoscopy;VCOL, virtual colonoscopy.
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ence patterns with face validity and in line with a priori
hypotheses. Choice-format stated preference methods
are particularly appropriate when it is important to
quantify relative preferences for speciﬁc attributes,
including aspects of both process and outcome, of a
service or technology. CRC screening is a particularly
relevant application because there are multiple screen-
ing strategies available that differ substantially with
regard to the process, preparation, and recommended
frequency of testing. Our ﬁndings emphasize the
important role of patient preferences in CRC screening
[12,13]—we found that accuracy as measured by sen-
sitivity and speciﬁcity is substantially more important
than process-related features and there is considerable
diversity in preferences of demographic subgroups in
the population. In this article, we adopted a public
health perspective to examine how overall population
uptake is affected by the features and availability of
CRC screening test modalities. Further research is war-
ranted to examine the role of patient preferences for
other attributes of the CRC program beyond the
uptake of the initial CRC screening test. The clinical
assessment of risk in determining which tests are
appropriate for individual patients is also an important
consideration.
These study results are timely for Canadian health
policy because formal CRC screening programs have
not been implemented in Canada. FOBT, to the exclu-
sion of alternative CRC screening modalities, has been
recommended by the National Committee on CRC
Screening for CRC screening programs [71] because
FOBT is the only modality with randomized clinical
trial data showing a reduction in mortality [78–81].
CRC screening with FOBT is currently the only
approach being evaluated in a pilot test program in
Ontario [7] because data from randomized clinical
trials are limited to CRC screening with FOBT
[79–81]. However, FOBT is the least preferred CRC
screening modality among the alternatives. Thus, our
ﬁndings are relevant in the context of understanding
patient decisions about the uptake of CRC screening
and may help to inform health policy about CRC
screening programs.
What are the implications of this study for devel-
oping and targeting future CRC screening modalities,
particularly as they extend beyond the Canadian
context? The results from choice-format stated prefer-
ence surveys can also be used to estimate preferences
for services or technologies that are not currently avail-
able. For example, although the performance of virtual
COL in clinical practice remains controversial [52,70],
it is less invasive than conventional COL. Our ﬁndings
suggest that virtual COL would be preferred over all
existing CRC screening modalities. Fecal DNA assays
been suggested to offer a high speciﬁcity of almost
100% but only a modest sensitivity of approximately
50% [37] and would not be preferred over existing
alternatives except FOBT. Focusing exclusively on
FOBT may not be the optimal approach to implemen-
tation of CRC screening in Canada. We also found that
providing a range of screening options is most likely to
increase utilization—an important lesson for screening
programs in other countries as well. In conclusion, the
results of this study suggest that there is a need to
consider patient preferences and diversity to optimize
uptake of CRC screening.
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Appendix A. Attributes and Levels Used in the Stated Preference Survey
Attributes
Attribute description as
presented to patients Levels Level description as presented to patients
Process How is it done? Stool You place 2 stool samples onto special cards for 3
consecutive days and return them to your doctor
Scope A ﬂexible tube with a small camera at the tip is
inserted into your rectum and through your colon
CT You lie on a special table while a machine moves
around you and takes x-ray pictures (like a CAT scan)
Enema
and X-ray
Air and a white liquid are injected into your colon
through a rectal tube. x-ray pictures are taken as the
liquid moves through your colon*
Pain Is there pain or
discomfort?
None
Mild
You feel no pain during the test
You may feel mild pain or discomfort during the test*
Preparation What do you do to prepare? None
Diet
No preparation required
You must alter your diet for 5 days by avoiding some
speciﬁc foods and over-the-counter medications
Enem/lax Before the test you must take laxatives or enemas
which cause diarrhea to clean your colon*
Speciﬁcity Is it accurate if you
DO NOT have cancer?
100% If you DO NOT have cancer, the test result will never
say you may have cancer. No other test is needed.
80% If you DO NOT have cancer, the test result will say
you may have cancer 2 out of 10 times.You then
need to have a different test done
50% If you DO NOT have cancer, the test result will say
you may have cancer 5 out of 10 times.You then
need to have a different test done.*
Sensitivity Is it accurate if
you DO have cancer?
90% If you DO have cancer, the test will miss it 1 out of
10 times
70% If you DO have cancer, the test will miss it 3 out of
10 times
40% If you DO have cancer, the test will miss it 6 out of
10 times*
Cost How much would
you pay?
$10 $10
$50 $50
$250 $250
$500 $500
*Reference level for attribute.
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Appendix B. Survey Preamble and Example of Stated Preference Survey ChoiceTask
Doctors may recommend that their patients consider screening for colon cancer. Suppose your own doctor
recommended this for you.
The ﬁrst part of this survey has 12 questions. In each question there are two tests, Test A and Test B, which are
ways to screen for colon cancer. Please mark the test you would prefer. Some of the tests shown are not available
now, but could be available in the future. When you answer each question, imagine that the options shown are the
only ones available to you.
Each test includes a cost. Please ASSUME THAT THIS IS WHAT YOU WOULD HAVE TO PAY TO HAVE
THE TEST DONE, and that YOU WOULD NOT LOSE INCOME IF YOU MISS TIME FROM WORK.
Depending on your situation this COST could include costs for any of the following:
• medication;
• materials to prepare for the test (e.g., laxatives or enemas);
• child care;
• transportation to go to the hospital or doctor’s ofﬁce (e.g., parking, gas, taxi).
PLEASE ASSUME THAT NONE OF THESE COSTS ARE COVERED by the government or your private
insurance.
When comparing the different colon cancer screening tests, please consider how their associated costs would
affect your household budget. For example, paying $75 means that you have $75 less to spend on something else.
The following table shows an example question.
Features Test A Test B
How is it done? You place 2 stool samples onto
special cards for 3 consecutive days
and return them to your doctor
A ﬂexible tube with a small camera at
the tip is inserted into your rectum and
through your colon
Is there pain or discomfort? You feel no pain during the test You may feel mild pain or discomfort
during the test
What do you do to prepare? You must alter your diet for 5 days
by avoiding some speciﬁc foods and
over-the-counter medications
Before the test you must take laxatives
or enemas which cause diarrhea to
clean your colon
Is it accurate if you DO NOT have cancer? If you DO NOT have cancer, the
test result will say you may have
cancer 5 out of 10 times.You then
need to have a different test done
Same as for Test A
Is it accurate if you DO have cancer? If you DO have cancer, the test will
miss it 3 out of 10 times
Same as for Test A
How much would you pay? $50 $250
Which test would you prefer (please mark one box only) Prefer A  Prefer B 
Suppose you now have the option of no screening.
What would you prefer now?
(please mark one box only)
I would still prefer the test
chosen above

I would prefer no screening 
The ﬁrst part of the question shows two ways to screen for colon cancer and asks which you would prefer. In this case, the person indicated that he/she preferred Test A over
Test B. Even if you do not like either test, please mark the one you would prefer if you had to choose one.
The second part of the question asks if you would still prefer screening if you had the option of no screening. In this case the person indicated he/she would prefer no screening.
There is no right answer.We are interested in your preferences.
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Appendix C. Words andTheir Meanings
Colon cancer is a disease that can affect your colon or rectum.
Colon cancer is as common in men as it is in women. In 1998,
6500 Ontarians received a diagnosis of colon cancer and 2200
people died of the disease. It is the third leading cancer killer in
North America.
This survey asks about colon cancer screening. Screening
means testing for cancer even when you have NO problems or
symptoms and everything is working FINE. Screening for
cancer may ﬁnd cancer or precancerous growths (polyps) when
they are much easier to treat and more likely to be cured.
There are many ways to screen for colon cancer. For
example, one way involves taking stool samples with a kit and
sending them to a lab. Others are done at your doctor’s ofﬁce
or in a hospital where the inside of the colon and rectum is
examined with special cameras or x-rays.
In this survey you may ﬁnd words you do not understand.
The following table explains some of these words. You can
refer to this table as you answer the survey.
Word Meaning
1. Cancer A disease where cells in one part of the body grow much more than normal.
2. CAT scan or CT scan A special x-ray test, where you lie on a table that moves through a ring.
A camera spins around inside the ring and takes x-ray pictures.
3. Colon The colon is the lower part of your intestine (see diagram). It is also called the large intestine or bowel.
4. Enema A liquid that is inserted into the rectum to clean the lower part of the bowel.
5. Laxative A medicine that you take by mouth to make your bowels move. Some laxatives cause diarrhea.
6. Mammogram A test where x-rays are taken of your breasts.
7. Polyp A growth on the lining of the colon (see diagram) that could turn into cancer if it is not removed.
8. Rectum The rectum is the last part of your colon (see diagram).
9. Stool Product of bowel movement.
Diagram: Digestive System
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